ABBV - AbbVie Inc logo

AbbVie Inc

ABBV

AbbVie Inc. develops, manufactures, and sells a range of biopharmaceuticals, focusing on autoimmune diseases, blood cancers, migraine treatments, and dermatological products. Its portfolio includes Skyrizi, Rinvoq, Botox, and various eye care medications.

⚕️ Healthcare NYSE Listed 2013 $ USD
$1,000 invested 10 years ago →$7,029today

Score Overview

1 Year
Score
Net Growth49.55%
Net TrendGrew
Net Income Consistency—
Rev Growth5.27%
Rev TrendGrew
Revenue Consistency—
5 Years
Score5.1
Net Growth-45.24%
Net Trend40%
Net Income Consistency—
Rev Growth14.57%
Rev Trend80%
Revenue Consistency—
10 Years
Score
Net Growth6.16%
Net Trend50%
Net Income Consistency
Rev Growth151.14%
Rev Trend90%
Revenue Consistency
All Time
Score
Net Growth53.10%
Net Trend54%
Net Income Consistency
Rev Growth242.66%
Rev Trend92%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where AbbVie Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ABBV does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 285.19—
1 Year2025-10-22
$ 222.0328.44%
5 Years2021-10-22
$ 91.38212.09%
10 Years2016-10-21
$ 40.587x
All Time2013-01-02
$ 20.2914x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 64.38B$ 6.32B
2025$ 61.16B$ 4.22B$ 5.25B
2024$ 56.33B$ 4.27B$ 5.55B
2023$ 54.31B$ 4.86B$ 12.81B
2022$ 58.05B$ 11.83B$ 9.22B
2021$ 56.19B$ 11.54B$ 9.83B
2020$ 45.80B$ 4.61B$ 8.47B
2019$ 33.26B$ 7.88B$ 39.92B
2018$ 32.75B$ 5.68B$ 8.06B
2017$ 28.21B$ 5.30B$ 9.78B
2016$ 25.63B$ 5.95B$ 6.42B
2015$ 22.85B$ 5.14B$ 8.40B
2014$ 19.96B$ 1.77B$ 8.37B
IPO2013$ 18.79B$ 4.12B$ 9.89B
ABBV - AbbVie Inc logo

AbbVie Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 45.80B to $ 61.16B and net income declined from $ 4.61B to $ 4.22B. Revenue increased in 4 of those 5 years; net income in 2.

Between 2015 and 2025, revenue grew from $ 22.85B to $ 61.16B and net income declined from $ 5.14B to $ 4.22B. Revenue increased in 9 of those 10 years; net income in 5.

AbbVie Inc currently holds a 5-year HDB Score of 5.1 out of 10. How the HDB Score is calculated.

Membership

Explore ABBV with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies